Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17812980 | 0.77 | KDM4E (0.38) | KDM4EPOLBMAPTTDP1L3MBTL1 | |
| SCHEMBL21637950 | 0.77 | MAPT (0.38) | KDM4EPOLBMAPTTDP1L3MBTL1 | |
| SCHEMBL12139313 | 0.77 | TDP1 (0.40) | KDM4EMAPTTDP1L3MBTL1ALDH1A1 | |
| SCHEMBL4940111 | 0.74 | ALDH1A1 (0.53) | KDM4EPOLBALDH1A1HPGDHSD17B10 | |
| SCHEMBL29449705 | 0.71 | POLB (0.60) | KDM4EPOLBMAPTTDP1L3MBTL1 | |
| SCHEMBL653948 | 0.71 | POLB (0.60) | KDM4EPOLBMAPTTDP1L3MBTL1 | |
| SCHEMBL8338791 | 0.70 | SLC6A4 (0.41) | KDM4EPOLBMAPTALDH1A1 | |
| SCHEMBL514292 | 0.69 | TSHR (0.45) | ALDH1A1TSHRIDO1 | |
| SCHEMBL1642155 | 0.69 | TSHR (0.45) | MAPTTDP1ALDH1A1HSD17B10TSHR | |
| SCHEMBL6508099 | 0.69 | TSHR (0.45) | MAPTTDP1ALDH1A1HSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067607-B2 | Potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100004229-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2010-01-07 | — | — | US | disclosed |
| EP-1041986-A4 | PHARMACEUTICALLY ACTIVE COMPOUND AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE INC (US) | 2001-03-21 | — | — | EP | disclosed |
| EP-1041986-A1 | PHARMACEUTICALLY ACTIVE COMPOUND AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 2000-10-11 | — | — | EP | disclosed |
| CN-1045768-C | Angiotension II antagonists | LILLY CO ELI (US) | 1999-10-20 | — | — | CN | disclosed |
| WO-1999018962-A1 | PHARMACEUTICALLY ACTIVE COMPOUND AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-04-22 | — | — | WO | disclosed |
| CN-1085897-A | Angiotension II antagonists | LILLY CO ELI (US) | 1994-04-27 | — | — | CN | disclosed |
| US-4440964-A | INTERMEDIATES FOR PREPARING SUBSTITUTED ANILINES | MONSANTO COMPANY (US) | 1984-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004229-A1 | Potassium Channel Inhibitors | KCNJ2, KCNH2, KCNH3 | KDM4E 418/4885POLB 4635/4885MAPT 2186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.